Hesseling Anneke C, Blakney Anna K, Jones Christine E, Esser Monika M, de Beer Corena, Kuhn Louise, Cotton Mark F, Jaspan Heather B
Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa.
Division of Immunology, Institute of Infectious Disease and Molecular Medicine and Clinical Laboratory Sciences, University of Cape Town, South Africa; Department of Bioengineering, University of Washington, Seattle, WA, USA.
Vaccine. 2016 Jul 12;34(32):3702-9. doi: 10.1016/j.vaccine.2016.03.081. Epub 2016 Apr 4.
Bacille Calmette-Guérin (BCG) is routinely given at birth in tuberculosis-endemic settings due to its protective effect against disseminated tuberculosis in infants. BCG is however contraindicated in HIV-infected infants. We investigated whether delaying BCG vaccination to 14 weeks of age affected vaccine-induced antibody responses to Haemophilus influenzae type b (Hib)-conjugate, pertussis, tetanus and Hepatitis B (HBV) vaccines, in HIV-exposed uninfected (HEU) and -unexposed uninfected (HUU) infants.
Infants were randomized to receive BCG at birth or at 14 weeks of age. Blood was taken at 14, 24, and 52 weeks of age and analyzed for Hib, pertussis, tetanus and HBV specific antibodies.
BCG was given either at birth (106 infants, 51 HEU) or at 14 weeks of age (74 infants, 50 HEU). The timing of BCG vaccination did not influence the antibody response to any antigen studied. However, in a non-randomized comparison, HEU infants had higher Hib antibody concentrations at weeks 14 and 24 (p=0.001 and <0.001, respectively) and pertussis at week 24 (p=0.003). Conversely, HEU infants had lower antibody concentrations to HBV at 14 and 52 weeks (p=0.032 and p=0.031) with no differences in tetanus titres.
HIV exposure, but not the timing of BCG vaccination, was associated with antibody concentrations to Hib, pertussis, HBV and tetanus primary immunization.
DOH-27-1106-1520.
由于卡介苗（BCG）对婴儿播散性结核病具有保护作用，在结核病流行地区通常在出生时接种。然而，HIV感染婴儿禁忌接种卡介苗。我们调查了将卡介苗接种推迟至14周龄是否会影响暴露于HIV但未感染（HEU）和未暴露于HIV且未感染（HUU）婴儿对b型流感嗜血杆菌（Hib）结合疫苗、百日咳、破伤风和乙型肝炎（HBV）疫苗的疫苗诱导抗体反应。
将婴儿随机分为出生时或14周龄时接种卡介苗。在14、24和52周龄时采集血液，分析Hib、百日咳、破伤风和HBV特异性抗体。
106名婴儿（51名HEU）在出生时接种卡介苗，74名婴儿（50名HEU）在14周龄时接种卡介苗。卡介苗接种时间不影响对所研究任何抗原的抗体反应。然而，在非随机比较中，HEU婴儿在14周和24周时Hib抗体浓度较高（分别为p=0.001和<0.001），在24周时百日咳抗体浓度较高（p=0.003）。相反，HEU婴儿在14周和52周时对HBV的抗体浓度较低（p=0.032和p=0.031），破伤风抗体滴度无差异。
HIV暴露而非卡介苗接种时间与Hib、百日咳、HBV和破伤风初次免疫的抗体浓度有关。
DOH-27-1106-1520。
